Bristol-Myers Squibb
PulseAugur coverage of Bristol-Myers Squibb — every cluster mentioning Bristol-Myers Squibb across labs, papers, and developer communities, ranked by signal.
5 day(s) with sentiment data
-
Pharma pivots to specialized treatments amid patent cliff concerns
The pharmaceutical industry is shifting its focus from blockbuster drugs to specialized, personalized treatments due to impending patent cliffs. This strategic pivot aims to identify new revenue streams, with a target o…
-
Anthropic uses Claude AI to speed up drug development with partners
Anthropic is leveraging its Claude AI model to accelerate drug development through research partnerships with six organizations, including BigHat Biosciences and Bristol Myers Squibb. The company is also initiating its …
-
Bristol-Myers Squibb invests $3B in AI drug success predictor
Bristol-Myers Squibb (BMS) has reportedly invested $3 billion into an artificial intelligence model designed to predict the success rate of new drugs. This AI aims to calculate the probability of success for drug candid…
-
AI Productivity Gains Spark Debate on Employee vs. Company Benefits
As artificial intelligence tools like GPT-4 and Claude 3 become more integrated into the workplace, business leaders are grappling with how to distribute the resulting productivity gains. Companies such as PepsiCo, Inde…
-
Biotech IPOs surge with over two dozen companies public this year
The biotech sector has seen a significant increase in companies going public this year, with over two dozen already having completed their IPOs. This trend is expected to continue, with more companies preparing to enter…
-
AI Enhances Antibody Design, But Lab Work Remains Crucial
Artificial intelligence has shown promise in enhancing the design of therapeutic antibodies, according to a recent study. While AI can improve existing drug candidates, the research emphasizes that traditional laborator…
-
N+1 Data Center Cooling Designs Hide Critical Shared-Control Failure Domains
Data centers often employ N+1 cooling designs, which appear resilient on paper with redundant components like pumps and air handlers. However, a hidden failure domain can emerge if these redundant units share a single c…
-
New two-step method simplifies antibody-drug conjugate creation for cancer therapies
Researchers have developed a novel two-step process for creating more uniform antibody-drug conjugates (ADCs). This method precisely attaches cancer drugs to a specific site on antibodies, streamlining the development o…
-
PhyMamba framework enhances battery health prognostics with physics-modulated Mamba
Researchers have developed PhyMamba, a novel two-stage framework that integrates physics-based modeling with Mamba sequence modeling for improved battery health prognostics. This approach enhances long-horizon health fo…
-
AI hardware and infrastructure recognized as distinct asset class by investors
A chipmaker has secured investment deals where investors are now considering AI hardware and infrastructure as a distinct asset class. This development signifies the growing systemic importance of the AI industry, poten…
-
AstraZeneca, Bristol Myers Squibb reportedly explore merger talks
AstraZeneca and Bristol Myers Squibb have reportedly engaged in early-stage merger discussions, though the talks are not guaranteed to result in a transaction. Such a combination would create a pharmaceutical giant with…
-
Warren Buffett warns against speculative investing, highlighting biotech's gambling-like risks
Warren Buffett has cautioned against the increasing speculative nature of the stock market, drawing a parallel to the biotechnology sector. He noted that while he prefers businesses he can understand with predictable ca…
-
Bristol Myers Squibb deploys NVIDIA's most advanced AI factory for drug discovery
Bristol Myers Squibb is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, built on the new DGX Vera Rubin NVL72 systems. This advanced infrastructure will provide all scientists with…
-
LFP Battery Safety and Evangelion Series Trailer Released
This cluster covers two distinct topics: the safety of Lithium Iron Phosphate (LFP) batteries, particularly in scenarios where the Battery Management System (BMS) fails, and the release of the first English trailer for …
-
BMS Mumbai center emphasizes need for explainable AI in insurance
BMS has opened a new center in Mumbai, emphasizing the growing need for AI solutions in the insurance brokerage sector. The company highlights that to effectively scale complex operations, AI must be inherently explaina…
-
Healthcare M&A Surges to $65B Amid Patent Cliffs and Global Innovation
The pharmaceutical industry is experiencing a significant surge in mergers and acquisitions, with $65 billion in deals during the first quarter of 2026. This trend is driven by looming patent expirations for major drugs…
-
Bristol-Myers Squibb deploys Anthropic's Claude for drug discovery
Bristol-Myers Squibb, a major pharmaceutical company, is implementing Anthropic's Claude across its 30,000 employees for various functions including drug discovery and operational tasks. This partnership positions Claud…
-
Pharma leaders seek stable FDA amid pricing policy concerns
Pharmaceutical industry leaders are advocating for stability and predictability from the next Food and Drug Administration (FDA) commissioner following a period of leadership changes and uncertainty. CEOs from major dru…
-
Axios Future of Health Summit 2026 to Convene Healthcare Leaders
Axios will host its second annual Future of Health Summit on Wednesday, May 13, 2026, featuring discussions on the evolving healthcare landscape. The event will convene various leaders from the health, technology, and p…
-
Hengrui inks $15.2B global drug development deal with BMS
Chinese pharmaceutical company Hengrui has entered into a global collaboration and licensing agreement with US giant Bristol Myers Squibb (BMS). The deal, valued at up to US$15.2 billion, involves the development of 13 …